StreetInsider.com News Articles

Form 10-Q Biofrontera Inc. For: Jun 30

Thu, 13 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260813/26922170.html

Form 10-Q Biofrontera Inc. For: Jun 30

Thu, 13 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260813/26922170.html

Form 8-K Biofrontera Inc. For: Aug 13

Thu, 13 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260813/26917476.html

Form 8-K Biofrontera Inc. For: Aug 13

Thu, 13 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260813/26917476.html

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

Thu, 13 Aug 2026 08:51:00 -0400

WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.

Second Quarter 2026 Highlights

Net product revenue of $12.0 million, an increase of 32.9% compared to $9.0 million in the prior-year period.
Gross margin of 80%, compared to 71% in the prior-year period, an improvement of approximately 920 basis points, reflecting the lower Ameluz^® cost structure established following the closing of

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

Thu, 13 Aug 2026 08:51:00 -0400

Second Quarter 2026 Highlights

Net product revenue of $12.0 million, an increase of 32.9% compared to $9.0 million in the prior-year period.
Gross margin of 80%, compared to 71% in the prior-year period, an improvement of approximately 920 basis points, reflecting the lower Ameluz^® cost structure established following the closing of

Form SCHEDULE 13G/A Biofrontera Inc. Filed by: Rosalind Advisors, Inc.

Wed, 12 Aug 2026 14:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26912017.html

Form SCHEDULE 13G/A Biofrontera Inc. Filed by: Rosalind Advisors, Inc.

Wed, 12 Aug 2026 14:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26912017.html

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

Wed, 05 Aug 2026 16:15:00 -0400

WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz^® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED^® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.

Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.

Conference Call and Webcast Details

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

Wed, 05 Aug 2026 16:15:00 -0400

Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.

Conference Call and Webcast Details

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

Wed, 05 Aug 2026 16:15:00 -0400

Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.

Conference Call and Webcast Details

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

Wed, 05 Aug 2026 16:15:00 -0400

Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update.

Conference Call and Webcast Details

Form 4 Biofrontera Inc. For: Jul 28 Filed by: Luebbert Hermann

Wed, 29 Jul 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260729/26836697.html

Form 4 Biofrontera Inc. For: Jul 28 Filed by: Luebbert Hermann

Wed, 29 Jul 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260729/26836697.html

Form 4 Biofrontera Inc. For: Jul 28 Filed by: Leffler Eugene Frederick

Wed, 29 Jul 2026 17:44:00 -0400

si-local-file:///var/storage/secattach/20260729/26836689.html

Form 4 Biofrontera Inc. For: Jul 28 Filed by: Leffler Eugene Frederick

Wed, 29 Jul 2026 17:44:00 -0400

si-local-file:///var/storage/secattach/20260729/26836689.html

Form S-8 Biofrontera Inc.

Wed, 22 Jul 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260722/26802746.html

Form S-8 Biofrontera Inc.

Wed, 22 Jul 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260722/26802746.html

Form 10-K/A Biofrontera Inc. For: Dec 31

Wed, 22 Jul 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260722/26802314.html

Form 10-K/A Biofrontera Inc. For: Dec 31

Wed, 22 Jul 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260722/26802314.html

Form 8-K Biofrontera Inc. For: Jun 11

Wed, 17 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260617/26659832.html

Form 8-K Biofrontera Inc. For: Jun 11

Wed, 17 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260617/26659832.html

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Thu, 21 May 2026 09:15:00 -0400

WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.

Company Webcast

The webcast presentation will take place at 11:00 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2026/ or directly at

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Thu, 21 May 2026 09:15:00 -0400

Company Webcast

Benchmark Downgrades Biofrontera (BFRI) to Speculative Buy

Tue, 19 May 2026 08:01:58 -0400

(Updated - May 19, 2026 8:01 AM EDT)

Benchmark analyst Bruce Jackson downgraded Biofrontera (NASDAQ: BFRI) from Buy to Speculative Buy with a price target of $3.00.

The analyst comments "Biofrontera reported in line 1Q results and reiterated its plans to break even on an operating cash flow basis for 2026, driven by a combination of accelerating revenue growth, lower cost of goods due to the renegotiated relationship with Biofrontera AG, and disciplined expense management. Management expects revenue growth to accelerate into 2027 as new labelling indications for superficial Basal Cell Carcinoma (sBCC) and extremities expand the potential market for Ameluz. Upcoming